Provided by
| Consensus (mean) in EUR million | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 E |
|---|---|---|---|---|---|
| Orders received | 1,083 | 1,281 | 1,092 | 1,373 | 1,197 |
| - Biomaterial Solutions and Services | 738.0 | 908.0 | 693.0 | 994.0 | 789.4 |
| - Process Performance Solutions | 345.0 | 372.0 | 400.0 | 379.0 | 407.7 |
| Net sales | 1,295 | 1,477 | 1,244 | 1,315 | 1,333 |
| - Biomaterial Solutions and Services | 934.0 | 1,067.0 | 904.0 | 945.0 | 904.1 |
| - Process Performance Solutions | 361.0 | 410.0 | 341.0 | 370.0 | 426.7 |
| Comparable EBITA | 159 | 196 | 114 | 152 | 165 |
| - Biomaterial Solutions and Services | 89.0 | 123.0 | 64.0 | 98.0 | 93.4 |
| - Process Performance Solutions | 79.0 | 90.0 | 63.0 | 69.0 | 84.1 |
| Comparable EBITA Margin (%) | 12.3% | 13.3% | 9.2% | 11.5% | 12.4% |
| - Biomaterial Solns. and Servs. | 9.5% | 11.6% | 7.1% | 10.4% | 10.4% |
| - Process Perf. Solns. | 21.9% | 21.9% | 18.5% | 18.7% | 19.6% |
| Reported EPS | 0.46 | 0.57 | 0.19 | 0.40 | 0.50 |